Literature DB >> 20837128

Extended exposure to dietary melatonin reduces tumor number and size in aged male mice.

Edward H Sharman1, Kaizhi G Sharman, Stephen C Bondy.   

Abstract

Several sets of male mice were given dietary melatonin over a series of experiments performed during a nine year period. Overall, melatonin-supplemented mice aged ≥26 months at sacrifice had significantly fewer tumors with lower severity than similarly aged control animals. The studies were originally designed to explore the potential of this agent for reducing the rate of onset of some genetic indices of brain aging. When these animals were sacrificed they were routinely examined for overt evidence of tumors and when these were found, a note was made of their occurrence, and of their size. Tumors are commonly found during senescence of several strains of mice. Since tumorigenesis was not the original intent of the study, these observations were recorded but not pursued in greater detail. In this report, these data have now been collated and summarized. This analysis has the disadvantage that tumor origin and morphology were not recorded. However, the study also has the advantage of being conducted over an extended period of time with many groups of animals. In consequence, many extraneous factors, which could be potential confounders, such as seasonal or dietary variations, are unlikely to have interfered with the analysis. The use of more than one mouse strain strengthens the possibility that the findings may have general relevance. Both aged and young animals were included in the original experiments but the tumor incidence in animals younger than 25 months was very low.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837128      PMCID: PMC2998564          DOI: 10.1016/j.exger.2010.09.004

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  42 in total

Review 1.  Circulating melatonin and the risk of breast and endometrial cancer in women.

Authors:  Akila N Viswanathan; Eva S Schernhammer
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

2.  Lipocalin 2 promotes breast cancer progression.

Authors:  Jiang Yang; Diane R Bielenberg; Scott J Rodig; Robert Doiron; Matthew C Clifton; Andrew L Kung; Roland K Strong; David Zurakowski; Marsha A Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 3.  Therapeutic actions of melatonin in cancer: possible mechanisms.

Authors:  Venkataramanujan Srinivasan; D Warren Spence; Seithikurippu R Pandi-Perumal; Ilya Trakht; Daniel P Cardinali
Journal:  Integr Cancer Ther       Date:  2008-09       Impact factor: 3.279

4.  Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine.

Authors:  Perumal Subramanian; Shankaran Mirunalini; Kadiyala Babu Dakshayani; Seithikurippu R Pandi-Perumal; Ilya Trakht; Daniel P Cardinali
Journal:  J Pineal Res       Date:  2007-10       Impact factor: 13.007

5.  Beneficial properties of melatonin in an experimental model of pancreatic cancer.

Authors:  Juan F Ruiz-Rabelo; Reyes Vázquez; María D Perea; Adolfo Cruz; Raul González; Ana Romero; María C Muñoz-Villanueva; Isaac Túnez; Pedro Montilla; Jordi Muntané; Francisco Javier Padillo
Journal:  J Pineal Res       Date:  2007-10       Impact factor: 13.007

6.  Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice.

Authors:  B B Otálora; J A Madrid; N Alvarez; V Vicente; M A Rol
Journal:  J Pineal Res       Date:  2008-04       Impact factor: 13.007

7.  Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index.

Authors:  Katrin Hoffmann; Martin J Firth; Alex H Beesley; Joseph R Freitas; Jette Ford; Saranga Senanayake; Nicholas H de Klerk; David L Baker; Ursula R Kees
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

8.  Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion.

Authors:  Haihua Zhang; Liyan Xu; Dawei Xiao; Jianjun Xie; Hongmei Zeng; Zhaoyang Wang; Xiaoling Zhang; Yongdong Niu; Zhongying Shen; Jinghui Shen; Xuan Wu; Enmin Li
Journal:  J Clin Pathol       Date:  2007-04-05       Impact factor: 3.411

9.  Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats.

Authors:  Takuji Tanaka; Yumiko Yasui; Mayu Tanaka; Takahiro Tanaka; Takeru Oyama; K M Wahidur Rahman
Journal:  Chem Biol Interact       Date:  2008-11-05       Impact factor: 5.192

10.  Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer.

Authors:  Tatsuhiko Kakisaka; Tadashi Kondo; Tetsuya Okano; Kiyonaga Fujii; Kazufumi Honda; Mitsufumi Endo; Akihiko Tsuchida; Tatsuya Aoki; Takao Itoi; Fuminori Moriyasu; Tesshi Yamada; Harubumi Kato; Toshihide Nishimura; Satoru Todo; Setsuo Hirohashi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-01       Impact factor: 3.205

View more
  3 in total

Review 1.  The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.

Authors:  Subhankar Chakraborty; Sukhwinder Kaur; Sushovan Guha; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2012-03-31

Review 2.  Molecular mechanisms of melatonin's inhibitory actions on breast cancers.

Authors:  Sara Proietti; Alessandra Cucina; Russel J Reiter; Mariano Bizzarri
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

Review 3.  Mechanisms Underlying Tumor Suppressive Properties of Melatonin.

Authors:  Stephen C Bondy; Arezoo Campbell
Journal:  Int J Mol Sci       Date:  2018-07-27       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.